digital phenotyping lean body mass
Top Clinicians Reveal Semaglutide Outshines Tirzepatide
Patients on tirzepatide lose about 3.5% lean body mass in 12 weeks, nearly double the 1.7% loss seen with semaglutide. This difference emerged from a digital phenotyping study using smartphone data, which tracked thousands of patients in real time. Medical Disclaimer: This article is for informational purposes only